Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

20.05USD
15 Dec 2017
Change (% chg)

$-0.84 (-4.02%)
Prev Close
$20.89
Open
$21.00
Day's High
$21.15
Day's Low
$19.73
Volume
1,535,188
Avg. Vol
204,700
52-wk High
$53.89
52-wk Low
$19.73

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 4.21
Market Cap(Mil.): $1,122.56
Shares Outstanding(Mil.): 28.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

09 Nov 2017

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

06 Nov 2017

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

23 Oct 2017

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

29 Aug 2017

BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement

* ‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​

28 Aug 2017

BRIEF-Five Prime Therapeutics Q2 loss per share $1.58

* Five Prime announces second quarter 2017 results and provides business update

08 Aug 2017

BRIEF-Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018

* Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development

17 Jul 2017

BRIEF-Five Prime Therapeutics says Lewis Williams to be chairman of board in 2018

* Five Prime Therapeutics announces Lewis T. "Rusty" Williams plans to transition from CEO to executive chairman of the board in 2018

21 Jun 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,850 +6.50
Novartis AG (NOVN.S) CHF83.80 -0.05
AstraZeneca plc (AZN.L) 4,881.00 -3.50
Eli Lilly and Co (LLY.N) $86.54 +0.04
ArQule, Inc. (ARQL.OQ) $1.50 +0.01

Earnings vs. Estimates